The fluorescence in situ hybridization (FISH) study for the most common AML related chromosome changes was normal. DNA probes specific for oncogenes or chromosome regions at 5q33, 7q31, RUNX1T1/RUNX1, KMT2A (MLL), PML/RARA, and CBFB showed normal hybridization signals in all interphase cells examined.

SPECIFIC PROBE RESULTS:

5q: NORMAL
   nuc ish 5q33(CSF1R,RPS14)x2[100]

7q: NORMAL
   nuc ish 7q31(MDICx2)[100]
   RUNX1T1/RUNX1: NORMAL
   nuc ish 8q21(RUNX1T1x2),21q22(RUNX1x2)[100]

KMT2A (MLL): NORMAL
   nuc ish 11q23(KMT2Ax2)[100]

PML/RARA: NORMAL
   nuc ish 15q24(PMLx2),17q21(RARAx2)[100]
### CBFB: NORMAL

nuc ish 16q22(CBFBx2) [100]

This analysis is limited to abnormalities detectable by the specific probes included in the study. FISH results should be interpreted within the context of a full cytogenetic analysis and hematologic evaluation.

This test was developed and its performance characteristics determined by Laboratory Corporation of America Holdings (LabCorp). It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary.

**Director Review:** Inder K. Gadi, PhD, FACMG

---

**For inquiries, the physician may contact**

**Branch:** 800−222−7566  **Lab:** 800−735−4087
FISH RESULT: NORMAL AML PANEL

INTERPRETATION:

The fluorescence in situ hybridization (FISH) study for the most common AML related chromosome changes was normal. DNA probes specific for oncogenes or chromosome regions at 5q33, 7q31, RUNX1T1/RUNX1, KMT2A (MLL), PML/RARA, and CBFB showed normal hybridization signals in all interphase cells examined.

SPECIFIC PROBE RESULTS:

5q: NORMAL
   nuc ish 5q33(CSF1R,RPS14)x2[100]

7q: NORMAL
   nuc ish 7q31(MDFICx2)[100]

RUNX1T1/RUNX1: NORMAL
   nuc ish 8q21(RUNX1T1x2),21q22(RUNX1x2)[100]

KMT2A (MLL): NORMAL
   nuc ish 11q23(KMT2Ax2)[100]

PML/RARA: NORMAL
   nuc ish 15q24(PMLx2),17q21(RARAx2)[100]

CBFB: NORMAL
   nuc ish 16q22(CBFBx2)[100]

This analysis is limited to abnormalities detectable by the specific probes included in the study. FISH results should be interpreted within the context of a full cytogenetic analysis and hematologic evaluation.

This test was developed and its performance characteristics determined by Laboratory Corporation of America Holdings (LabCorp). It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary.
Client/Sending Facility:
LabCorp Test Master
Test Account
3060 South Church Street
Burlington, NC  27215
Ph:  (336)436-8645
POE-00

LCLS Specimen Number:  257-225-9011-0
Patient Name:  SAMPLE REPORT, 510336
Date of Birth:  06/12/1985
Gender:  F
Account Number:  90000999
Patient ID:
Lab Number:  YU16-72760  F

Ordering Physician:  
Specimen Type:  BLOOD
Client Reference:  
Date Collected:  09/13/2016
Date Received:  09/14/2016

Inder K. Gadi, PhD, FACMG
Board Certified Cytogeneticist

Arundhati Chatterjee, MD
Medical Director
Peter Papenhausen, PhD
National Director of Cytogenetics

Technical component performed by Laboratory Corporation of America Holdings,
1904 TW Alexander Drive , RTP , NC , 27709-0153   (800) 345-4363
Professional Component performed by LabCorp CLIA 34D1008914, 1904 TW Alexander Dr, Research Triangle Park, NC 27709. Medical Director, Arundhati Chatterjee, MD. Integrated Oncology is a brand used by Esoterix Genetic Laboratories, LLC, a wholly-owned subsidiary of Laboratory Corporation of America Holdings.

This document contains private and confidential health information provided by state and federal law.
The AML panel fluorescence in situ hybridization (FISH) study was abnormal. FISH results were positive for the RUNX1T1/RUNX1 (ETO-AML1) gene fusion. The presence of fusion signals is associated with a translocation 8;21, the prototype anomaly of the AML, M2 subclass. In those cases where blood is submitted for FISH, the results should be interpreted in conjunction with PMN ratios.

DNA probes specific for oncogenes or chromosome regions at 5q33, 7q31, KMT2A (11q23), PML/RARA [t(15;17)] and CBFB (inv 16) showed normal hybridization signals in all interphase cells examined.

This analysis is limited to abnormalities detectable by the specific probes included in the study (about 80% of AML clones with cytogenetically apparent alterations). Cytogenetic analysis targets clones with proliferative advantage and is comprehensive in its coverage.

SPECIFIC PROBE RESULTS:

RUNX1T1/RUNX1: ABNORMAL
nuc ish(RUNX1T1x3), (RUNX1x3) (RUNX1T1 con RUNX1x2) [96/100]
### SAMPLE REPORT, 510336

<table>
<thead>
<tr>
<th>TESTS</th>
<th>RESULT</th>
<th>FLAG</th>
<th>UNITS</th>
<th>REFERENCE INTERVAL</th>
<th>LAB</th>
</tr>
</thead>
<tbody>
<tr>
<td>5q:</td>
<td>NORMAL nuc ish(CSF1R,RPS14)x2[100]</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>7q31:</td>
<td>NORMAL nuc ish(MDFICx2)[100]</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>KMT2A:</td>
<td>NORMAL nuc ish(KMT2Ax2)[100]</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PML/RARA:</td>
<td>NORMAL nuc ish(PML,RARA)x2[100]</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CBFB:</td>
<td>NORMAL nuc ish(CBFBx2)[100]</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

FISH results should be interpreted within the context of a full hematopathology evaluation.

This test was developed and its performance characteristics determined by Laboratory Corporation of America Holdings (LabCorp). It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research.

Director Review: Inder K. Gadi, PhD, FACMG

---

©2004–16 Laboratory Corporation of America ® Holdings
All Rights Reserved

DOC1 Ver: 1.49
The AML panel fluorescence in situ hybridization (FISH) study was abnormal. FISH results were positive for the RUNX1T1/RUNX1 (ETO-AML1) gene fusion. The presence of fusion signals is associated with a translocation 8;21, the prototype anomaly of the AML, M2 subclass. In those cases where blood is submitted for FISH, the results should be interpreted in conjunction with PMN ratios.

DNA probes specific for oncogenes or chromosome regions at 5q33, 7q31, KMT2A (11q23), PML/RARA [t(15;17)] and CBFB (inv 16) showed normal hybridization signals in all interphase cells examined.

This analysis is limited to abnormalities detectable by the specific probes included in the study (about 80% of AML clones with cytogenetically apparent alterations). Cytogenetic analysis targets clones with proliferative advantage and is comprehensive in its coverage.

**SPECIFIC PROBE RESULTS:**

**RUNX1T1/RUNX1: ABNORMAL**

nuc ish(RUNX1T1x3), (RUNX1x3) (RUNX1T1 con RUNX1x2) [96/100]

5q: NORMAL nuc ish(CSF1R,RPS14)x2[100]

7q31: NORMAL nuc ish(MDFICx2)[100]

KMT2A: NORMAL nuc ish(KMT2Ax2)[100]

PML/RARA: NORMAL nuc ish(PML,RARA)x2[100]

CBFB: NORMAL nuc ish(CBFBx2)[100]

FISH results should be interpreted within the context of a full hematopathology evaluation.

This test was developed and its performance characteristics determined by Laboratory Corporation of America Holdings (LabCorp). It has not been cleared or approved by the U.S. Food and Drug Administration. The FDA has determined that such
LCLS Specimen Number: 257-225-9012-0
Patient Name: SAMPLE REPORT, 510336
Date of Birth: 06/12/1985
Gender: F
Patient ID:
Lab Number: YU16-72762 F

Account Number: 90000999
Ordering Physician:
Specimen Type: BONE MARROW
Client Reference:
Date Collected: 09/13/2016
Date Received: 09/14/2016

clearance or approval is not necessary. This test is used for clinical purposes. It should not be regarded as investigational or for research.

Inder K. Gadi, PhD, FACMG
Board Certified Cytogeneticist

Arundhati Chatterjee, MD
Medical Director

Peter Papenhausen, PhD
National Director of Cytogenetics

Technical component performed by Laboratory Corporation of America Holdings, 1904 TW Alexander Dr, RTP, NC 27709-0153 (800) 345-4363
Professional Component performed by LabCorp CLIA 34D1008914, 1904 TW Alexander Dr, Research Triangle Park, NC 27709. Medical Director, Arundhati Chatterjee, MD.
Integrated Oncology is a brand used by Esoterix Genetic Laboratories, LLC, a wholly-owned subsidiary of Laboratory Corporation of America Holdings.
This document contains private and confidential health information protected by state and federal law.